The SELECT trial is a major breakthrough, says Yale Medicine cardiologist Harlan Krumholz, MD, SM, explaining that while semaglutide [given as Ozempic] was already known to lower the risk of heart disease in people with diabetes, the SELECT trial was the first to show that Wegovy, which contains a higher dose of semaglutide, also lowers that risk even in people who dont have diabetes
Global metabolomics discovers two novel biomarkers in pyridoxine-dependent epilepsy caused by ALDH7A1 deficiency
This formulation is intended strictly for laboratory and scientific research use
these changes may be a sign of degradation or contamination
Strengths and limitations In this study, we used the TriNetX platform to integrate and analyze anonymized longitudinal electronic health record (EHR) data
GLP-1 drugs shattered that assumption